[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
October 18, 2006

Sirolimus-Eluting Stents vs Brachytherapy for Restenosis

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(15):1837-1838. doi:10.1001/jama.296.15.1837-c

To the Editor: Dr Holmes and colleagues1 reported the results of the Sirolimus-Eluting Stent vs Brachytherapy in Patients With Bare Metal In-Stent Restenosis (SISR) trial, in which they demonstrated that sirolimus-eluting stents are superior to brachytherapy in patients with in-stent restenosis. Rather than merely abandoning brachytherapy because of logistical difficulties, it would be helpful if the authors provided additional information.

×